Cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Catalytic efficiency: Fusion of certain peptides allow for greater catalytic efficiency by altering the tertiary and quaternary structure of the target protein. Solubility: A common challenge in fusion protein design is the issue of insolubility of newly synthesized fusion proteins in the recombinant host, leading to an over-aggregation of the target protein in the cell. Molecular chaperones that are able to aid in protein folding may be added, thereby better segregating hydrophobic and hydrophilic interactions in the solute to increase protein solubility. Thermostability: Singular peptides or protein fragments are typically added to reduce flexibility of either the N or C terminus of the target protein, which reinforces thermostability and stabilizes pH range. Enzyme activity: Fusion that involves the introduction of hydrogen bonds may be used to expand overall enzyme activity. Expression levels: Addition of numerous fusion fragments, such as maltose binding protein (MBP) or small ubiquitin-like molecule (SUMO), serve to enhance enzyme expression and secretion of the target protein. Immobilization: PHA synthase, an enzyme that allows for the immobilization of proteins of interest, is an important fusion tag in industrial research. Crystal quality: Crystal quality can be improved by adding covalent links between proteins, aiding in structure determination techniques.
. In normal liquids, most of this crossover takes place at frequencies between GHz and THz, sometimes called hypersound. At sub-GHz frequencies, a normal liquid cannot sustain shear waves: the zero-frequency limit of the shear modulus is 0. This is sometimes seen as the defining property of a liquid. However, like the bulk modulus K, the shear modulus G is also frequency-dependent and exhibits a similar crossover at hypersound frequencies. According to linear response theory, the Fourier transform of K or G describes how the system returns to equilibrium after an external perturbation; for this reason, the dispersion step in the GHz to THz region is also called relaxation. As a liquid is supercooled toward the glass transition, the structural relaxation time exponentially increases, which explains the viscoelastic behavior of glass-forming liquids.
== Functions == Lpp, along with another OmpA-like lipoprotein called Pal/OprL (P0A912), maintains the stability of the cell envelope by attaching the outer membrane to the cell wall. Lpp has been proposed as a virulence factor of Yersinia pestis, the cause of plague. Y. pestis needs lpp for maximum survival in macrophages and to efficiently kill mouse models of bubonic and pneumonic plague.
After being re-elected, Bush signed into law a Medicare drug benefit program which, according to Jan Crawford, resulted in "the greatest expansion in America's welfare state in forty years" – the bill's costs approached $7 trillion. In 2007, Bush opposed and vetoed State Children's Health Insurance Program (SCHIP) legislation, which was added by the Democrats onto a war funding bill and passed by Congress. The SCHIP legislation would have significantly expanded federally funded healthcare benefits and plans to children of some low-income families. It was to be funded by an increase in the cigarette tax. Bush viewed the legislation as a move toward socialized health care, and asserted that the program could benefit families making as much as $83,000 per year who did not need the help. On May 21, 2008, Bush signed into law the Genetic Information Nondiscrimination Act, aimed to protect Americans against health insurance and employment discrimination based on a person's genetic information. The issue had been debated for 13 years before it finally became law. The measure is designed to protect citizens without hindering genetic research.
== The encounter between biochemistry and genetics == The development of molecular biology is also the encounter of two disciplines which made considerable progress in the course of the first thirty years of the twentieth century: biochemistry and genetics. The first studies the structure and function of the molecules which make up living things. Between 1900 and 1940, the central processes of metabolism were described: the process of digestion and the absorption of the nutritive elements derived from alimentation, such as the sugars. Every one of these processes is catalyzed by a particular enzyme. Enzymes are proteins, like the antibodies present in blood or the proteins responsible for muscular contraction. As a consequence, the study of proteins, of their structure and synthesis, became one of the principal objectives of biochemists. The second discipline of biology which developed at the beginning of the 20th century is genetics. After the rediscovery of the laws of Mendel through the studies of Hugo de Vries, Carl Correns and Erich von Tschermak in 1900, this science began to take shape thanks to the adoption by Thomas Hunt Morgan, in 1910, of a model organism for genetic studies, the famous fruit fly (Drosophila melanogaster). Shortly after, Morgan showed that the genes are localized on chromosomes. Following this discovery, he continued working with Drosophila and, along with numerous other research groups, confirmed the importance of the gene in the life and development of organisms.
Sources: en.wikipedia.org
=== PVAT AND ET-1 === ET-1 In addition to its direct vasoconstrictor effects, it causes changes in visceral and perivascular adipose tissue (PVAT), and may contribute to the pathogenesis of both insulin resistance and vascular dysfunction/damage. Perivascular adipose tissue seems to have anti contractile effect and this dilator effect was lost in obese patients. secondary to obesity, ET-1 high level changes on PVAT will lead to PVAT hypertrophy which will be associated with reduced partial oxygen pressure, an increase in the production of inflammatory cytokines such as TNF-α and IL-6, and elevation of reactive oxygen species. Thus, oxidative stress and hypoxia may promote imbalance in the production of vasoactive compounds and may affect vascular homeostasis by activating the ET-1 system.
=== EC 1.17.1 With NAD or NADP as acceptor === EC 1.17.1.1: CDP-4-dehydro-6-deoxyglucose reductase EC 1.17.1.2: now classified as EC 1.17.7.4, 4-hydroxy-3-methylbut-2-enyl diphosphate reductase EC 1.17.1.3: leucoanthocyanidin reductase EC 1.17.1.4: xanthine dehydrogenase EC 1.17.1.5: nicotinate dehydrogenase EC 1.17.1.6: Now EC 1.17.99.5, bile-acid 7α-dehydroxylase. It is now known that FAD is the acceptor and not NAD+ as was thought previously EC 1.17.1.7: Now EC 1.2.1.91, 3-oxo-5,6-dehydrosuberyl-CoA semialdehyde dehydrogenase EC 1.17.1.8: 4-hydroxy-tetrahydrodipicolinate reductase EC 1.17.1.9: formate dehydrogenase EC 1.17.1.10: formate dehydrogenase (NADP+) EC 1.17.1.11: formate dehydrogenase (NAD+, ferredoxin)
== Diseases == Mesotheliomas are neoplasms that are relatively specific for serous membranes. The modified Müllerian-derived serous membranes that surrounds the ovaries in females can give rise to serous tumors, a solid to papillary tumor type that may also arise within the uterus.
=== Chemical === Different chemical procedures for the conversion into final products or the removal of pollutants are used for the safe disposal of contaminants. Pre-chlorination for algae control and arresting biological growth. Aeration along with pre-chlorination for removal of dissolved iron when present with relatively small amounts of manganese. Disinfection for killing bacteria, viruses and other pathogens, using chlorine, ozone and ultra-violet light.
The deficiency in anchoring fibrils impairs the adherence between the epidermis and the underlying dermis. This deficiency occurs due to the genetic mutation(s) in the COL7A1 gene in chromosome 3. The COL7A1 gene in chromosome 3 is responsible for coding for type VII collagen, a protein that assists in helping anchor the epidermis and dermis. Thus, the skin of DEB patients is highly susceptible to mild to severe blistering, depending on the subtype. Collagen VII is also associated with the epithelium of the esophageal lining, and DEB patients may have chronic scarring, webbing, and obstruction of the esophagus. Affected individuals are often severely malnourished due to trauma to the oral and esophageal mucosa and require feeding tubes for nutrition. They also have iron-deficiency anemia of uncertain origin, which leads to chronic fatigue. Open wounds on the skin heal slowly or not at all, often scarring extensively, and are particularly susceptible to infection. Many individuals bathe in a bleach and water mixture to fight off these infections. The chronic inflammation leads to errors in the DNA of the affected skin cells, which in turn causes squamous cell carcinoma (SCC). The majority of these patients die before the age of 30, either of SCC or complications related to DEB. The chronic inflammatory state seen in recessive dystrophic epidermolysis bullosa (RDEB) may cause small fiber peripheral neuropathy (SFN). RDEB patients have reported the sensation of pain in line with neuropathic pain qualities.
Sources: en.wikipedia.org
In 1900, the German colonial administration of Nauru granted phosphate rights to British businessman John T. Arundel's Pacific Islands Company (PIC). The PIC was replaced by the Pacific Phosphate Company (PPC) in 1902, with German interests holding around one-third of the company's share capital. Production commenced in 1906, largely relying on indentured labour, with Australia and New Zealand as the primary markets. In 1914, following the outbreak of the First World War, the Australian Naval and Military Expeditionary Force occupied Nauru, with an agreement reached whereby the Australian military would assume administrative control of the island and the PPC would continue phosphate operations. Following the end of the war, Nauru was made a League of Nations mandate under the joint trusteeship of Australia, New Zealand and the United Kingdom, with Australia retaining administration of the island. In 1919, the three trustees signed the Nauru Island Agreement, which entitled them to the phosphate of Nauru through the British Phosphate Commissioners. They bought back all the assets of the PPC for more than 3.5 million pounds on 1 July 1920, and started to manage it directly on 1 January 1921, after a six-month transition period of PPC management. Most of PPC's former employees were retained by the BPC.
==== Live delivery systems ==== Live delivery systems, also known as vectors, are cells modified with ligands or antigens to improve the immunogenicity of recombinant subunits via altering antigen presentation, biodistribution and trafficking. Subunits may either be inserted within the carrier or genetically engineered to be expressed on the surface of the vectors for efficient presentation to the mucosal immune system.
== External links == An Extremely Detailed Map of the 2024 Election from The New York Times "Misinformation Dashboard: Election 2024. A tool tracking the topics and tactics of 2024 election misinformation". News Literacy Project. 2024. Retrieved September 30, 2024. Dovere, Edward-Isaac (November 6, 2024). "Where Harris' campaign went wrong". CNN. Retrieved November 7, 2024. "The Choice 2024: Harris vs. Trump". Frontline. Season 43. Episode 2. September 24, 2024. PBS. WGBH. Retrieved November 28, 2024. "The VP Choice: Vance vs. Walz". Frontline. Season 43. Episode 3. October 8, 2024. PBS. WGBH. Retrieved November 28, 2024.
=== Trace fossils === The Ediacaran fossils of Southern Australia contain trace fossils, which indicate that there were motile benthic organisms. The organisms that produced the traces in the sediments were all worm-like sediment feeders or detritus feeders (Detritivore). There are a few trace fossils, which resemble arthropod trails. Evidence suggests that arthropod-like organisms existed during the Precambrian. This evidence is in the type of trails left behind; specifically one specimen that shows six pairs of symmetrically placed impressions, which resemble trilobite walking trails.
The educational experience of many Colombian children begins with attendance at a preschool academy until age five (Educación preescolar). Basic education (Educación básica) is compulsory by law. It has two stages: Primary basic education (Educación básica primaria) which goes from first to fifth grade – children from six to ten years old, and Secondary basic education (Educación básica secundaria), which goes from sixth to ninth grade. Basic education is followed by Middle vocational education (Educación media vocacional) that comprises the tenth and eleventh grades. It may have different vocational training modalities or specialties (academic, technical, business, and so on.) according to the curriculum adopted by each school.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.